All Serina Therapeutics, Inc. Articles
“Is The Beaten Down Biotech Sector The Smartest Bet In Today’s Volatile Market?” – ( $SER $XBI $IBB $PFE )
In the bustling digital amphitheater of Tribe Public’s latest CEO Presentation, the question of the hour was as sharp as it was timely: “Is the beaten down biotech sector the smartest bet in today’s volatile market?” With a flourish of slides and a dash of optimism, Steven A. Ledger, the...
Jun 16, 2025
View Article
Biotech Funding in 2025: A Wild Ride Through Uncertainty – ( $IBB $XBI $SER )
The biotech sector, long known for its rollercoaster fortunes, is currently experiencing a particularly stomach-churning drop. If the industry were an amusement park, the “Trump Policy Plunge” would be its latest and most daunting attraction—one that’s left investors clutching their wall...
Jun 09, 2025
View Article
Serina Therapeutics Strategically Adds Karuna Therapeutics’ CMO Dr. Stephen Brannan: A Power Move for CNS Innovation & Beyond ( $SER $BMY $TAK $NVS $LLY )
In the ever-evolving world of neuroscience drug development, on May 22, Serina Therapeutics (NYSE American: SER) announced that they have added a formidable new player to its Board of Directors: Dr. Stephen Brannan, a name that resonates with both gravitas and a touch of clinical stardust. Annou...
Jun 04, 2025
View Article
Serina Therapeutics (NYSE: SER) Secures JuvVentures (UK) Limited Equity Premium Financing To Advance Parkinson’s Disease Trials
Serina Therapeutics (NYSE: SER, $4.91) has secured the second $5 million tranche of a $10 million equity financing deal, strengthening its financial position as it prepares to advance its lead Parkinson's disease candidate, SER-252, into Phase 1 clinical trials in late 2025. In a financial maneuver ...
Feb 03, 2025
View Article
Stay Informed. Stay Competitive.
Vista Partners offers an exclusive newsletter and content with daily, weekly, monthly and quarterly investing ideas, strategies, and marketing insights.
We value your privacy and will never share your information.
